General Proximity

The next generation of induced-proximity medicines.

San Francisco, United States · Founded 2019 · $16.0M raised

Employees
11–50
Founded
2019
Business Model
B2B
Total Funding
$16.0M
Last Round
Venture RoundMay 2026
Rounds
3

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

General Proximity is a San Francisco biotechnology platform company pioneering next-generation induced proximity medicines for undruggable targets. Its proprietary OmniTAC platform enables precise modification of disease-driving proteins across oncology, cardiometabolic disease, neurodegeneration, and longevity. Backed by Felicis, Y Combinator, age1, and ARPA-H grants.

Summary

General Proximity is a Biotech company based in San Francisco, United States, founded in 2019. It has raised $16.0M in total across 3 rounds, most recently a Venture Round in May 2026. Investors include Felicis Ventures, age1 and Rock Creek Capital.

Tech & App Stack

5 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Venture RoundVenture RoundMay 2026

Sign up to see all 3 events

Funding: Pre-Seed through Venture Round. Amounts, valuations, and investors where available.

Investors

Similar Companies

AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech, Drug Discovery
Private EquityTotal funding$2.3BFeb 2020
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
Eikon TherapeuticsIPO

Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...

Hayward, United States201–500Artificial Intelligence, Biotech
Series DTotal funding$1.1BFeb 2025
Xaira Therapeutics

Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intellig...

South San Francisco, United States51–200Artificial Intelligence, Biotech
Series ATotal funding$1.0BApr 2024
OricIPO

San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...

South San Francisco, United States51–200Biotech, Healthcare
Private EquityTotal funding$647.0MFeb 2026
Neumora TherapeuticsIPO

Clinical-stage biopharmaceutical developing precision medicines targeting novel mechanisms to tre...

Watertown, United States51–200Biotech, Drug Discovery
Series BTotal funding$612.0MOct 2022

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

General Proximity on Indexed.vc
<a href="https://indexed.vc/companies/generalproximity"><img src="https://indexed.vc/api/badge/company/generalproximity" alt="General Proximity on Indexed.vc" width="260" height="76" /></a>